Clinical Trial

GNT Induction Treatment in Locally Advanced NPC

Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated September 7, 2023 (before its estimated September 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
The goal of this clinical trial is to compare overall response rate between gemcitabine, nimotuzumab and toripalimab as induction treatment and gemcitabine combined with cisplatine in paitents with locally advanced nasopharyngeal carcinoma. It aims to answer whether gemcitabine, nimotuzumab and toripalimab as induction treatment show non-inferiority compared to GP induction chemotherapy. Participants will be randomly divided into two induction treatment groups.
Trial Details
NCT Number NCT06026878
Lead Sponsor Air Force Military Medical University, China
Conditions Nasopharyngeal Carcinoma
Enrollment 228 participants
Start Date 2023-09-01
Primary Completion 2025-09-30 (estimated)
Study Completion 2027-09-30 (estimated)
Updated on ClinicalTrials.gov 2023-09-07